ProfileGDS4814 / ILMN_1867517
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 67% 69% 67% 69% 68% 71% 72% 71% 72% 73% 69% 71% 66% 70% 69% 64% 71% 70% 69% 65% 70% 68% 70% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)65.117567
GSM780708Untreated after 4 days (C2_1)69.889169
GSM780709Untreated after 4 days (C3_1)64.230667
GSM780719Untreated after 4 days (C1_2)71.128369
GSM780720Untreated after 4 days (C2_2)67.986168
GSM780721Untreated after 4 days (C3_2)76.509371
GSM780710Trastuzumab treated after 4 days (T1_1)82.223472
GSM780711Trastuzumab treated after 4 days (T2_1)75.718371
GSM780712Trastuzumab treated after 4 days (T3_1)82.588672
GSM780722Trastuzumab treated after 4 days (T1_2)87.84973
GSM780723Trastuzumab treated after 4 days (T2_2)70.759769
GSM780724Trastuzumab treated after 4 days (T3_2)76.551171
GSM780713Pertuzumab treated after 4 days (P1_1)63.401166
GSM780714Pertuzumab treated after 4 days (P2_1)72.739470
GSM780715Pertuzumab treated after 4 days (P3_1)68.633869
GSM780725Pertuzumab treated after 4 days (P1_2)60.040764
GSM780726Pertuzumab treated after 4 days (P2_2)76.647771
GSM780727Pertuzumab treated after 4 days (P3_2)73.514570
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)70.192669
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)60.351765
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)73.968370
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)66.557468
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)73.922970